MedTrace Logo

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

NCT00568841 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-09-17

No results posted yet for this study

Summary

This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

erlotinib

erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)

PROCEDURE

FDG-/FLT-PET

Sponsors & Collaborators

  • Lung Cancer Group Cologne

    lead OTHER

Principal Investigators

  • Juergen Wolf, Prof., Dr. · University Cologne, Lung Cancer Group Cologne

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568841 on ClinicalTrials.gov